

Wei Ding

Adjunct Clinical Associate Professor, Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **Pediatric Hematology/Oncology**

300 Pasteur Dr H314 MC 5208

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 724-5203

Bio

CLINICAL FOCUS

- Hematology

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2023)
- Board Certification: Hematology, American Board of Internal Medicine (2011)
- Fellowship: Mayo Clinic Hematology and Oncology Fellowship (2011) MN
- Residency: Mayo Clinic Internal Medicine Residency (2007) MN
- Medical Education: Beijing Medical University (1994) China

Publications

PUBLICATIONS

- **Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.** *Leukemia*
Hampel, P. J., Rabe, K. G., Wang, Y., Hwang, S. R., Kenderian, S. S., Muchtar, E., Leis, J. F., Koehler, A. B., Tsang, M., Hilal, T., Parrondo, R., Bailen, R. J., Schwager, et al
2024
- **Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL)**
Wang, Y., LaPlant, B. R., Parikh, S., Leis, J., Call, T. G., Shanafelt, T. D., He, R., Micallef, I. N., Nowakowski, G. S., Habermann, T., Witzig, T. E., Koehler, A. B., Hampel, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis (HCMBL).** *Blood advances*
Kleinstern, G., Boddicker, N. J., O'Brien, D. R., Allmer, C., Rabe, K. G., Norman, A. D., Griffin, R., Yan, H., Ma, T., Call, T. G., Bruins, L., Brown, S., Bonolo de Campos, et al
2024
- **Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.** *Blood*
Abdelbaky, S., Giacomelli, B., Rabe, K. G., Yamaguchi, K., Wu, Y. Z., Yan, H., Shanafelt, T. D., Parikh, S. A., Ding, W., Hampel, P. J., Brown, S., Cerhan, J. R., Vachon, et al
2024
- **PD-1 Expression in Lymphoma Cells Mediates Cellular Proliferation By Engaging Phosphatase SHP-1/SHP-2**

Sinha, S., Price-Troska, T., Tian, S., Sakemura, R., Yan, H., Boysen, J., Wang, Z., Wu, X., He, R., Shi, M., Wang, Y., Klee, E. W., Parikh, et al
AMER SOC HEMATOLOGY.2023

- **Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).**
Woyach, J., Yin, J., Brown, J. R., Dinner, S., Lozanski, G., Little, R. F., Miller, C., Damarla, V., Coutre, S. E., Ding, W., Hill, B. T., Burbano, G., Ruppert, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).**
Woyach, J., Yin, J., Brown, J. R., Dinner, S., Lozanski, G., Little, R. F., Miller, C., Damarla, V., Coutre, S. E., Ding, W., Hill, B. T., Perez Burbano, G., Ruppert, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy**
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K., Parikh, S. A., Coutre, S., Lozanski, et al
AMER SOC HEMATOLOGY.2021
- **Clinical Characteristics and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL), 80 Years of Age or Older**
Hampel, P., Call, T., Rabe, K., Achenbach, S., Muchtar, E., Kenderian, S., Wang, Y., Koehler, A., Leis, J., Schwager, S., Van Dyke, D., Shi, M., Hanson, et al
CIG MEDIA GROUP, LP.2021: S324-S325
- **Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index.** *Blood cancer journal*
Wang, Y., Achenbach, S. J., Rabe, K. G., Shanafelt, T. D., Call, T. G., Ding, W., Kenderian, S. S., Muchtar, E., Leis, J. F., Koehler, A. B., Schwager, S. M., Cerhan, J. R., Slager, et al
2021; 11 (8): 140
- **Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.** *Leukemia*
Ruppert, A. S., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Coutre, S., Brown, J. R., Nattam, S., Larson, R. A., Erba, H., Litzow, M., Owen, C., Kuzma, et al
2021
- **The CLL-international prognostic index (CLL-IPI) predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.** *Blood*
Parikh, S. A., Rabe, K. G., Kay, N. E., Call, T. G., Ding, W., Leis, J. F., Kenderian, S. S., Muchtar, E., Wang, Y., Koehler, A., Schwager, S. M., Lesnick, C., Kleinstern, et al
2021
- **The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).** *Vaccine*
Whitaker, J. A., Parikh, S. A., Shanafelt, T. D., Kay, N. E., Kennedy, R. B., Grill, D. E., Goergen, K. M., Call, T. G., Kendarian, S. S., Ding, W., Poland, G. A.
2021
- **Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma amongst chronic lymphocytic leukemia patients.** *Journal of the American Academy of Dermatology*
Kleinstern, G., Rishi, A., Achenbach, S. J., Rabe, K. G., Kay, N. E., Shanafelt, T. D., Ding, W., Leis, J. F., Norman, A. D., Call, T. G., Cerhan, J. R., Parikh, S. A., Baum, et al
2020
- **Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.** *Annals of hematology*
Archibald, W. J., Rabe, K. G., Kabat, B. F., Herrmann, J., Ding, W., Kay, N. E., Kenderian, S. S., Muchtar, E., Leis, J. F., Wang, Y., Chanan-Khan, A. A., Schwager, S. M., Koehler, et al
2020
- **Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index (CLL-IPI).**

Wang, Y., Achenbach, S. J., Rabe, K. G., Shanafelt, T. D., Call, T., Ding, W., Kenderian, S., Muchtar, E., Leis, J., Koehler, A., Schwager, S. M., Cerhan, J., Slager, et al
AMER SOC CLINICAL ONCOLOGY.2020

- **Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.**
Ruppert, A. S., Mandrekar, S. J., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Coutre, S. E., Brown, J. R., Nattam, S. R., Larson, R. A., Erba, H., Litzow, M., Owen, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.** *Cancer medicine*
Parikh, S. A., Achenbach, S. J., Call, T. G., Rabe, K. G., Ding, W., Leis, J. F., Kenderian, S. S., Chanan-Khan, A. A., Koehler, A. B., Schwager, S. M., Muchtar, E., Fonder, A. L., McCullough, et al
2020
- **The etiology of pleural effusions requiring thoracentesis in patients with chronic lymphocytic leukemia (CLL)**
Koehler, A., Aayed, A., Albitar, H., Call, T., Rabe, K., Ding, W., Kenderian, S., Leis, J., Muchtar, E., Hayman, S., Fonder, A., Schwager, S., Slager, et al
TAYLOR & FRANCIS LTD.2020: 229–31
- **Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index.** *American journal of hematology*
Kleinstern, G. n., O'Brien, D. R., Li, X. n., Tian, S. n., Kabat, B. F., Rabe, K. G., Norman, A. D., Yan, H. n., Vachon, C. M., Boddicker, N. J., Call, T. G., Parikh, S. A., Bruins, et al
2020
- **Atrial fibrillation (AF) in patients with CLL treated with ibrutinib: Assessing prediction models and clinical outcomes.**
Archibald, W., Rabe, K. G., Kabat, B., Call, T., Ding, W., Kay, N. E., Kenderian, S., Muchtar, E., Leis, J., Schwager, S. M., Koehler, A., Fonder, A. L., Slager, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice** *LEUKEMIA & LYMPHOMA*
Hampel, P. J., Ding, W., Call, T. G., Rabe, K. G., Kenderian, S. S., Witzig, T. E., Muchtar, E., Leis, J. F., Chanan-Khan, A. A., Koehler, A. B., Fonder, A. L., Schwager, S. M., Slager, et al
2019
- **Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.** *Leukemia & lymphoma*
Hampel, P. J., Ding, W. n., Call, T. G., Rabe, K. G., Kenderian, S. S., Witzig, T. E., Muchtar, E. n., Leis, J. F., Chanan-Khan, A. A., Koehler, A. B., Fonder, A. L., Schwager, S. M., Slager, et al
2019: 1–8
- **Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL** *NEW ENGLAND JOURNAL OF MEDICINE*
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., Parikh, S. A., Coutre, S., Hurria, et al
2018; 379 (26): 2517-2528
- **IGH translocations in chronic lymphocytic leukemia (CLL): clinicopathologic features and clinical outcomes.** *American journal of hematology*
Fang, H., Reichard, K. K., Rabe, K. G., Hanson, C. A., Call, T. G., Ding, W., Kenderian, S. S., Muchtar, E., Schwager, S. M., Leis, J. F., Chanan-Khan, A. A., Slager, S. L., Braggio, et al
2018
- **Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.** *The New England journal of medicine*
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., Parikh, S. A., Coutre, S., Hurria, et al
2018
- **Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)**
Boddicker, N. J., O'Brien, D. R., Braggio, E., Achenbach, S. J., Chaffee, K. G., Norman, A. D., Vachon, C. M., Kabat, B., Call, T. G., Parikh, S. A., Leis, J. F., Ding, W., Muchtar, et al

AMER SOC HEMATOLOGY.2018

- **Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202**

Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P., Rogers, K. A., Parikh, S. A., Coutre, S., Hurria, et al

AMER SOC HEMATOLOGY.2018

- **Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre** *BRITISH JOURNAL OF HAEMATOLOGY*

Hampel, P. J., Larson, M. C., Kabat, B., Call, T. G., Ding, W., Kenderian, S. S., Bowen, D., Boysen, J., Schwager, S. M., Leis, J. F., Chanan-Khan, A. A., Muchtar, E., Hanson, et al

2018; 183 (3): 421–27

- **Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis** *HAEMATOLOGICA*

Parikh, S. A., Chaffee, K. G., Larson, M. C., Hampel, P. J., Call, T. G., Ding, W., Kenderian, S. S., Leis, J. F., Chanan-Khan, A. A., Conte, M. J., Bowen, D., Schwager, S. M., Slager, et al

2018; 103 (6): E237–E240

- **Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.**

Hampel, P., Chaffee, K. G., Ding, W., Call, T., Kenderian, S., Muchtar, E., Leis, J., Chanan-Khan, A., Bowen, D., Fonder, A. L., Schwager, S. M., Slager, S. L., Shanafelt, et al

AMER SOC CLINICAL ONCOLOGY.2018

- **Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia** *EXPERT REVIEW OF HEMATOLOGY*

Kay, N. E., LaPlant, B. R., Pettinger, A. M., Call, T. G., Leis, J. F., Ding, W., Parikh, S. A., Conte, M. J., Bowen, D. A., Shanafelt, T. D.

2018; 11 (4): 337–49